Clinical Trial Update: Efficacy, Safety & Pharmacokinetic (PK) Study of HLD200 in Children Aged 4-5 Years With ADHD [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating HLD200 for Attention Deficit Hyperactivity Disorder in children aged 4-5 years was terminated; the update concerns its efficacy, safe…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Attention Deficit Hyperactivity Disorder

Drugs mentioned

• HLD200

Snippet

Sponsor: Ironshore Pharmaceuticals and Development, Inc | Conditions: Attention Deficit Hyperactivity Disorder | Phase 3 | Status: TERMINATED